US · Healthcare

Recce Pharmaceuticals Ltd (RECEF)

Biotechnology

Recce Pharmaceuticals Ltd (RECEF) is listed on US in the Healthcare sector. Industry: Biotechnology. As of 2026-05-23, reported P/E ratio is 25.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Download on the App Store Get it on Google Play

Key metrics for RECEF

P/E ratio

25.00

Recce Pharmaceuticals Ltd (RECEF) — FAQ

What is RECEF's P/E ratio?

The price-to-earnings (P/E) ratio for Recce Pharmaceuticals Ltd (RECEF) is 25.00 (data as of 2026-05-23).

Does Recce Pharmaceuticals Ltd pay a dividend?

Dividend yield is not available in the current snapshot for Recce Pharmaceuticals Ltd (RECEF). Check the MyAverix Finance app for the latest dividend data.

What sector is Recce Pharmaceuticals Ltd in?

Recce Pharmaceuticals Ltd (RECEF) is classified in the Healthcare sector (Biotechnology industry).

What exchange is RECEF listed on?

RECEF is listed on US.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Healthcare companies

Abbott Laboratories (ABT) AbbVie Inc. CDR (ABBV) Agilent Technologies Inc. (A1GI34) Aimed Bio (0009K0) Alnylam Pharmaceuticals, Inc. (A1LN34) Alvotech (ALVO) Amgen Inc (AMGN34) argenx SE (A1RG34)